Growing demand to overcome the limitations of the first-generation therapies, increasing cancer burden, expanding R&D activities, growing healthcare investments, and technological advancements are promoting the market growth.
Market Highlights: Mapping the U.S. Next Generation Immune Checkpoint Inhibitors Landscape
The next generation immune checkpoint inhibitors are advanced immunotherapy drugs, targeting newly identified immune checkpoint pathways to improve the immune system to fight against cancer more effectively. They help in enhancing immune response, reducing tumor progression, and overcoming resistance. This drives their adoption for cancer treatment, cold tumors treatment, as a combination therapy, and adjuvant therapy.
Global Market Growth
The global next-generation immune checkpoint inhibitors market size was estimated at USD 28.6 billion in 2025 and is predicted to increase from USD 32.55 billion in 2026 to approximately USD 104.18 billion by 2035, expanding at a CAGR of 13.8% from 2026 to 2035.
Expanding Innovations: Unlocking The Market Opportunities
The presence of advanced healthcare infrastructure is driving the adoption of the next-generation immune checkpoint inhibitors across the U.S. for the effective treatment of growing cancer cases.
- Increasing advancements in the discovery of novel checkpoint targets are also creating new opportunities.
- Growing demand for personalized immunotherapies is also promoting their adoption rates.
- A rise in health awareness is also increasing their use for early-stage cancer treatment.
- Expanding combination therapies and technological developments are also driving their innovations.
- A growth in the collaborations and government funding are also fueling their innovations and adoption.
The graph represents the estimated number of cancer cases and deaths in the U.S. for the year 2026. It indicates that there will be a rise in cancer burden, which will drive the demand for effective treatment options. This, in turn, will increase the adoption of next-generation immune checkpoint inhibitors to reduce the growing cancer burden across the U.S., which will ultimately promote the market growth.
Market Segmentation Overview
- By target type, the PD-1 inhibitors segment accounted for the highest revenue share of 34% of the U.S. next-generation immune checkpoint inhibitors market in 2025, due to their proven clinical success. Their high response and safety profile also increased their use. They were also used for combination therapies, where their enhanced approvals also increased their use.
- By drug class type, the monoclonal antibodies segment held a major revenue share of 52% of the U.S. market in 2025, due to their high specificity. Their proven effectiveness and sustained immune activation also increased their use. Their reduced off-target toxicity also increased their adoption rates.
- By therapy type, the combination therapy segment contributed the biggest revenue share of 62% of the U.S. next-generation immune checkpoint inhibitors market in 2025 and is expected to expand rapidly during the forecast period, due to their improved efficacy and synergistic mechanisms. Their ability to overcome resistance and enhance survival outcomes also increased their use. Their wide range of applications also increased their use.
- By indication type, the lung cancer segment held the largest revenue share of 30% of the U.S. market in 2025, due to growth in its incidence rates. This increased the use of next-generation immune checkpoint inhibitors due to their proven clinical success, effectiveness, and safety profile. High unmet needs also increased the adoption of combination therapies.
- By end user, the hospitals segment led the U.S. next-generation immune checkpoint inhibitors market with 58% in 2025, driven by high patient volume. Their multidisciplinary teams and advanced infrastructure have also increased the use of next-generation immune checkpoint inhibitors in hospitals. They also offered better patient monitoring and reimbursement policies, which increased their use.
Regional Analysis
The U.S. next-generation immune checkpoint inhibitors market held 32% share and is expected to show lucrative growth during the forecast period, due to growth in the cancer incidence rates. The presence of advanced healthcare systems and an advanced clinical trials ecosystem also increased the adoption of the next-generation immune checkpoint inhibitors. High healthcare spending, R&D investments, and the presence of advanced industries also increased their advancements, enhancing the market growth.
The Market Giants: Leading Players Dominating the U.S. Market
Bristol Myers Squibb held the dominant position in the market with its LAG-3 inhibitor, TIGIT, and TIM-3, where Merck & Co. was its closest competitor, which offered Vibostolimab and Favezelimab. F. Hoffmann-La Roche also held its position in the market with its Tiragolumab, where Regeneron Pharmaceuticals also contributed to the market growth with its Fianlimab and REGN6569.
Segments Covered in the Report
By Target Type
- PD-1 Inhibitors
- Monoclonal Antibodies
- Bispecific Antibodies
- PD-L1 Inhibitors
- Monoclonal Antibodies
- Antibody-Drug Conjugates (ADCs)
- CTLA-4 Inhibitors
- Monotherapy Agents
- Combination Agents
- LAG-3 Inhibitors
- Monoclonal Antibodies
- Combination Regimens
- TIM-3 Inhibitors
- Early-stage Biologics
- Combination Therapies
- TIGIT Inhibitors
- Monoclonal Antibodies
- Bispecific Antibodies
By Drug Class
- Monoclonal Antibodies
- Bispecific Antibodies
- Small Molecules
- Fusion Proteins
- Antibody-Drug Conjugates (ADCs)
By Therapy Type
- Monotherapy
- Combination Therapy
- Checkpoint + Chemotherapy
- Checkpoint + Targeted Therapy
- Checkpoint + Radiation Therapy
- Checkpoint + Other Immunotherapies
By Indication
- Lung Cancer
- Melanoma
- Renal Cell Carcinoma
- Head & Neck Cancer
- Bladder Cancer
- Breast Cancer
- Others
- Gastric Cancer
- Colorectal Cancer
By End User
- Hospitals
- Specialty Cancer Clinics
- Research Institutes
- Ambulatory Surgical Centers
